Bicara Therapeutics (NASDAQ:BCAX) Receives Outperform Rating from Wedbush
Bicara Therapeutics (NASDAQ:BCAX – Get Free Report)‘s stock had its “outperform” rating restated by Wedbush in a research note issued on Thursday,RTT News reports. They currently have a $31.00 target price on the stock. Wedbush’s price target suggests a potential upside of 131.34% from the stock’s current price. A number of other research firms also […]
Bicara Therapeutics (NASDAQ:BCAX – Get Free Report)‘s stock had its “outperform” rating restated by Wedbush in a research note issued on Thursday,RTT News reports. They currently have a $31.00 target price on the stock. Wedbush’s price target suggests a potential upside of 131.34% from the stock’s current price. A number of other research firms also […]
